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Abstract Receptor binding speci¢city is an essential element in
regulating the diverse activities of ¢broblast growth factors
(FGFs). FGF7 is ideal to study how this speci¢city is conferred
at the structural level, as it interacts exclusively with one
isoform of the FGF-receptor (FGFR) family, known as
FGFR2IIIb. Previous mutational analysis suggested the impor-
tance of the L4/L5 loop of FGF7 in speci¢c receptor recognition.
Here a theoretical model of FGFR2IIIb/FGF7 complex showed
that this loop interacts with the FGFR2IIIb unique exon. In
addition, the model revealed new residues that either directly
interact with the FGFR2IIIb unique exon (Asp63, Leu142) or
facilitate this interaction (Arg65). Mutations in these residues
reduced both receptor binding a⁄nity and biological activity of
FGF7. Altogether, these results provide the basis for under-
standing how receptor-binding speci¢city of FGF7 is conferred
at the structural level.
1 2003 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
The keratinocyte growth factor (KGF or FGF7) is a unique
member of the ¢broblast growth factor (FGF) family. Unlike
other FGFs that act on a wide spectrum of cell types, FGF7 is
a speci¢c mitogen for epithelial cells [1]. It is secreted by
stromal cells and stimulates the migration, di¡erentiation
and proliferation of a large variety of epithelial cells, acting
as a paracrine mediator of mesenchymal^epithelial communi-
cation [1^4]. FGF7 plays an important role in epithelial tissue
repair and development and is implicated in a number of
pathological conditions, including psoriasis, in£ammatory
bowel disease and cancer [4^7].
Two FGFs that show high homology to FGF7 have been
identi¢ed: FGF10 (also known as KGF2) and FGF22 [8,9].
Like FGF7, FGF10 and FGF22 act predominantly on cells of
epithelial origin. FGF22 is preferentially expressed in adult
skin and is involved in hair development [9], whereas
FGF10 was shown to be crucial for embryonic development
as FGF10-null mice die at birth due to lack of lung and limb
formation [10]. Based on their sequence homology and target
cell speci¢city, these three FGFs are classi¢ed as the FGF7
subfamily.
The biological activities of FGFs are mediated by cell-
surface high-a⁄nity receptors (FGFRs) that belong to the
tyrosine kinase receptor family. The prototype FGFR is
composed of an extracellular ligand binding domain that
contains three immunoglobulin-like domains (D1^D3), a
transmembrane domain, and a cytoplasmic domain that bears
the tyrosine kinase activity. Four high-a⁄nity receptors
(FGFR1^FGFR4) have been identi¢ed and alternative-splic-
ing mechanism generates FGFR isoforms with altered ligand
binding properties [11]. Unlike other FGFs that can interact
with several FGFRs, FGF7 subfamily members bind only one
receptor isoform, an alternatively spliced variant of FGFR2
that is speci¢cally expressed in epithelial cells (known as
KGFR or FGFR2IIIb). KGFR di¡ers from FGFR2 in the
carboxyl-terminal half of D3 that is encoded by the alterna-
tively spliced exon IIIb. The other ligand binding domains of
the receptor (D2, linker and amino-terminal half of D3) are
conserved between the two receptor isoforms.
The involvement of FGF7 subfamily members in a variety
of physiological processes and diseases, together with their
unique speci¢c interaction with the FGFR2IIIb, provides a
strong impetus for uncovering the structural basis of their
biological activities. A previous mutagenesis analysis study
in which large segments were exchanged between FGF7 and
FGF2 (an FGF that binds FGFR2IIIb poorly) suggested that
the amino-terminal part and a region in the middle of FGF7
determine its unique receptor binding speci¢city [12]. Further
mutagenesis analysis in FGF7 showed that residues compris-
ing the variable L4/L5 loop are crucial for the speci¢c recog-
nition of FGFR2IIIb, since exchanging this loop in FGF7
with the corresponding loop of FGF2 dramatically reduced
the ability of FGF7 to bind and activate the receptor. In
addition, point mutations in this loop of FGF7 reduced re-
ceptor binding and ability to activate the receptor [13]. Recent
resolution of the crystal structure of FGF10 bound to
FGFR2IIIb showed that similar interactions occur between
this growth factor and FGFR2IIIb, thus emphasizing the im-
portance of the L4/L5 loop and the amino-terminal part of
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FGF7 subfamily members for FGFR2IIIb-speci¢c recognition
[14].
The resolved structure also pointed to speci¢c residues with-
in the amino-terminal and middle part of FGF10 that are
engaged in intimate interactions with FGFR2IIIb [14]. To
determine whether the corresponding residues in FGF7 play
a similar role in receptor recognition, we mutated these resi-
dues in FGF7, and studied the e¡ect of these mutations on
receptor binding a⁄nity and biological activity. Altogether
our results suggest that the speci¢c recognition between
FGF7 subfamily members and FGFR2IIIb is determined by
homologous determinants in the ligands that interact with the
isoform-speci¢c domains in the receptor.
2. Materials and methods
2.1. Materials
Na125I (5000 Ci/mM) was a Du Pont-New England Nuclear prod-
uct. Heparin^Sepharose CL-6B was from Pharmacia LKB Biotech-
nology. Ni-NTA agarose was purchased from Qiagen. Fetal calf se-
rum (FCS) and media were purchased from Gibco-BRL. Fibronectin
was from Biological Industries (Beth-Haemek, Israel). Heparin from
bovine lung and other chemicals were purchased from Sigma.
2.2. Tissue culture
NIH/3T3 cells over-expressing FGFR2IIIb (NIH/KR cells) were
grown in DMEM containing 10% newborn calf serum [15]. Balb/
MK cells were grown in low-calcium media containing 5 ng/ml of
epidermal growth factor and 10% dialyzed FCS as previously de-
scribed [16]. The lymphocyte cell line BaF3 cells over-expressing
FGFR2IIIb (BaF/KR) were grown in RPMI 1640 supplemented
with 10% FCS and 10% IL-3 conditioned medium from WEHI-3B
cells [17].
2.3. Generation of point mutations in FGF7
FGF7 mutants were generated in three steps. First, a mutated seg-
ment encoding for the FGF7 amino-terminal part was created using
primer p1 (ATGGATCCATGGCTTGCAATGACATGACTCCA)
that is complementary to the N-terminal end of the FGF7 gene prod-
uct and contains an arti¢cial NcoI site (bold) 5P to the start codon,
and primers p2 (AGGAGGGGCTATAAGAGTGAGGAGACT-
CTTC), p3 (GGGGATATA GCAGTGAGAAGGCTCTTCTGT)
or p4 (ACTTCAAAGAAGCAATTCTGGAAAACCA) that contain
the appropriate point mutation (underlined: D63A, R65A and
L142A, respectively). A second mutated fragment, encoding for the
C-terminal part of FGF7, was created using primer p5 (TTGGATC-
CATTAAGTTATTGCCATAGGAAG) that is complementary to the
C-terminal end of the FGF7 gene product and contains an arti¢cial
BamHI site (bold) 3P to the stop codon, and primers p6 (GAA-
GAGTCTCCTCACTCTTATAGCCCCTCCT), p7 (ACAGAAGA-
GCCTTCTCACTGCTATATCCCC) or p8 (TGGTTTTCCAGA-
ATTGCTTCTTTGAAGT) that contain the appropriate point
mutation (underlined: D63A, R65A, L142A, respectively). The ampli-
¢ed products of the ¢rst step were annealed and ampli¢ed with prim-
ers p1 and p5. The obtained mutated FGF7 gene was cut with NcoI
and BamHI and cloned into pKM260 expression vector [13,18] that
was digested with the same enzymes. All mutated genes were se-
quenced to con¢rm that the desired mutation had been introduced
and that additional mutations had not been created during the am-
pli¢cation process.
2.4. Production and puri¢cation of the recombinant proteins
FGF7 and FGF7 mutants were expressed in BL21(DE3) PlysS cells
[19] and puri¢ed by Ni2þ-nitrilotriacetic acid a⁄nity chromatography
followed by heparin^Sepharose a⁄nity chromatography as previously
described [13,18]. All mutant proteins eluted from the column at the
same salt concentration as FGF7 (0.5 M NaCl). Thermal stability of
the R65A mutant was determined by incubating wild-type and mutant
protein at 37‡C in the presence of Balb/MK cells for 16 h. The me-
dium was then clari¢ed by centrifugation and tested for mitogenic
activity on Balb/MK cells as previously described [18].
2.5. Growth factor iodination, receptor binding, mitogenic assays and
cell proliferation assays
Radio-iodination of FGF7 and separation from free [125I]Na was
performed as previously described [20]. The speci¢c activities of radio-
iodinated FGF7 was in the range of 5U104 cpm/ng. Cell-surface
receptor binding competition assays were performed using subcon£u-
ent NIH/KR cultures in 24-well microtiter plates as described in
[12,20]. DNA synthesis was measured by a [3H]thymidine incorpora-
tion assay using serum-starved con£uent cultures of Balb/MK cells
[12,18]. For proliferation assays BaF/KR cells were seeded in 96-
well microtiter plates (2U104 cell/well). Fresh growth factors and
heparin were added every other day and viable cells were counted
on day 4 or 5 after seeding.
In each experiment, each data point was performed in duplicate and
each experiment was repeated at least three times. The variation be-
tween di¡erent experiments did not exceed 10%.
2.6. Molecular modeling of the FGF7:FGFR2IIIb complex
A model of the FGF7:FGFR2IIIb complex was generated by per-
forming a superposition of all CK coordinates from the crystal struc-
ture of free FGF7 (1QQK [21]) onto those of the bound FGF10 from
the crystal structure of the FGF10:FGFR2IIIb complex (1NUN [14])
using InsightII (Accylrys). The two FGFs share an overall similar
structure and superposition over all comparable CK atoms gives an
r.m.s.d. of 1.3 AQ . The ¢rst 24 amino-terminal residues of mature
FGF7 were not resolved in the 1QQK crystal structure and the coor-
dinates of Asp63 are not complete, thus the side chain of this residue
is not indicated in the model. It is noteworthy that an FGF7 deletion
mutant lacking the 28 amino-terminal residues of the mature FGF7
polypeptide retains potent biological activity [22].
3. Results
3.1. Structure prediction of FGF7 bound to FGFR2IIIb
In order to explore the structural basis of the speci¢c
interaction between the FGF7 subfamily members and
FGFR2IIIb, a theoretical structure-based model of FGF7
bound to FGFR2IIIb was generated by superimposing the
coordinates of the FGF7 3D structure [21] onto the FGF10
ligand in the recently resolved structure of the
FGF10:FGFR2IIIb complex [14], using the InsightII software
(Accylrys). Superposition of the free FGF7 and the bound
FGF10 results in an r.m.s.d. of 1.3 AQ over all K carbons.
Thus the two structures are generally similar, but do have
some structural di¡erences.
Similar to FGF10, FGF7 interacts with D2, linker and D3
of the receptor (see Fig. 1A). As found for other FGFs, most
of the interaction with D2 is between the conserved residues
Asn149, Tyr151, Leu189 and Met191 of FGF7 and the hydro-
phobic surface of D2 (formed by residues Lys164, Leu166,
Ala168 and Phe170) and residue Arg251 in the linker domain.
These observed interactions are conserved in all FGF:FGFR
complexes that have been resolved [23^26], supporting the
concept that these contacts provide general FGF^FGFR af-
¢nity.
On the other hand, the speci¢city of FGF7:FGFR2IIIb
recognition is determined by interactions between variable
domains in FGF7 and the C-terminal part of D3 that is
unique to FGFR2IIIb. The model predicts that FGF7 inter-
acts with three loops in D3: the LBP^LC loop, which is con-
served between FGFR2 isoforms, and the LCP^LE and LF^LG
loops, which are encoded by the alternatively spliced exon
IIIb and are therefore speci¢c to isoform FGFR2IIIb. As
shown in Fig. 1A, the variable L4/L5 loop of FGF7 intimately
interacts with the isoform-speci¢c LCP^LE loop of D3. This
¢nding is in agreement with previous mutagenesis analysis,
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which revealed that the L4/L5 loop of FGF7 is critical for the
speci¢c recognition of the FGFR2IIIb [13].
In addition, the model predicts that, as for FGF10, residues
from the highly variable amino terminus and from L-strand 8
of FGF7 are involved in binding to the isoform-speci¢c loops
of D3. Thus, Asp63 from the loop preceding L1 interacts with
Ser315 from the LCP^LE loop, and Leu142 from L8 interacts
with Tyr345 in the LF^LG loop. In addition, the model shows
that residue Arg65 from L1 contacts Gln285 in the conserved
LBP^LC loop of D3. However, this residue contributes indi-
rectly to FGF7/FGFR2IIIb-speci¢c interaction as it is en-
gaged in intermolecular hydrogen bonds with other residues
from the amino-terminus of FGF7, allowing them to interact
with the isoform-speci¢c loops of D3. In order to verify these
interactions, alanine scanning mutagenesis was performed in
these key residues of FGF7 and the e¡ect of the mutations on
FGF7 biological properties was determined.
3.2. Alanine scanning mutagenesis in FGF7
The mature FGF7 polypeptide (residues 31^194) fused to
Fig. 1. A model of the FGF7:FGFR2IIIb complex was generated as described in Section 2. A: Overall structure of the FGF7:FGFR2IIIb
complex. The D2, linker and D3 subdomains of the FGFR2IIIb protein are colored yellow, orange and red respectively, while FGF7 is colored
blue. The alternatively spliced second half of D3 is colored purple. FGF7 regions that interact with D3 are colored green. L1, L4 and L8 of
FGF7 and the LCP^LE loop of the receptor are labeled accordingly. B: Interaction domain between FGF7 and FGFR2IIIb in the vicinity of
the three mutations (in CPK colored stick representation) performed in this study. Residues of FGFR2IIIb that are in putative contact with
the mutated FGF7 residues are indicated as well. FGF7 and FGFR2IIIb are colored as in panel A.
Fig. 2. Receptor binding a⁄nity of FGF7 mutant proteins. A: 14% SDS^PAGE analysis of puri¢cation stages of FGF7 mutants. In each pan-
el: lane 1, induced bacterial lysate; lane 2, peak fraction from heparin^Sepharose column. Molecular size markers (in kDa) are indicated on
the left. The expected size of mutant FGF7 is indicated by an arrow on the right. B: Competitive binding of 125I^FGF7 to NIH/KR cells was
obtained by increasing concentrations of the indicated wild-type or mutant growth factors. The assay was performed as described in Section 2.
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an amino-terminus hexa-histidine (His6) tag was employed for
the mutagenesis analysis. As previously reported, this tag does
not change the biological properties of FGF7 [18]. The mu-
tant proteins were expressed in BL21(DE3) plysS cells as de-
scribed in Section 2. The cells were lysed and mutant proteins
were puri¢ed from the soluble fraction by two consecutive
puri¢cation steps: Ni2þ-nitrilotriacetic acid a⁄nity chroma-
tography followed by heparin^Sepharose a⁄nity chromatog-
raphy. The mutant proteins eluted from the heparin^Sephar-
ose column at the same salt concentration as parental FGF7
(0.5 M NaCl). The puri¢ed mutant proteins were homogene-
ous as evaluated by sodium dodecyl sulfate^polyacrylamide
gel electrophoresis (SDS^PAGE) analysis (see Fig. 2A).
The e¡ect of point mutations in FGF7 on FGFR2IIIb
binding a⁄nity was examined by binding competition assays
in NIH/3T3 cells over-expressing the receptor [15]. As shown
in Fig. 2B, substitution of Asp63 or Leu142 with alanine
resulted in six- and three-fold reduction, respectively, in re-
ceptor binding a⁄nity, whereas mutating Arg65 to alanine
severely compromised the ability to bind FGFR2IIIb. Half-
maximal competition of 125I^FGF7 binding occurred at 1000
ng/ml of the R65A mutant compared with 7 ng/ml of native
FGF7.
Next, we examined whether the mutations a¡ected the abil-
ity to activate FGFR2IIIb, by testing the ability of mutant
proteins to stimulate DNA synthesis in Balb/MK cells that
naturally express FGFR2IIIb, and to induce proliferation of
BaF3 cells that were engineered to over-express the receptor
(BaF/KR). As shown in Fig. 3, the biological activity of the
mutant proteins in both cell types correlated with their bind-
ing a⁄nity characteristics. Mutants D63A and L142A exhib-
ited three- to ¢ve-fold reduction in their ability to induce a
mitogenic response in Balb/MK cells (Fig. 3A) and prolifer-
ation in BaF/KR cells (Fig. 3B) compared to native FGF7.
The mitogenic activity of mutant R65A in Balb/MK cells was
200-fold lower compared to native FGF7 (EC50 of 1 ng/ml
and 200 ng/ml, respectively). Moreover, the R65A mutant
achieved only 60% of the maximal mitogenic response pro-
duced by native FGF7. This mutant exhibited a similar dra-
matically reduced proliferative potency in BaF/KR cells. The
correlation between reduction in receptor binding a⁄nity and
biological activity of the three mutants indicates that the mu-
tations had no e¡ect on their thermal stability. Nevertheless,
the thermal stability of mutant R65A was con¢rmed as de-
scribed in Section 2. The thermal stability assay, the location
of the three mutated residues on the surface of FGF7 [21] and
the fact that the three mutant proteins retained wild-type af-
¢nity for heparin, strongly suggest that these mutations do
not a¡ect the global structure of the proteins.
4. Discussion
Receptor binding speci¢city is essential for regulating the
multitude of biological activities of FGFs. Among FGFs,
FGF7 exhibits the highest degree of receptor binding speci¢c-
ity and is therefore ideal to study how speci¢city is conferred
at the structural level. In the present study, we took advantage
of the recently resolved FGF10:FGFR2IIIb complex in order
to identify new residues in FGF7 that contribute to its unique
interaction with FGFR2IIIb, and to corroborate the results
from previous mutagenesis studies.
We found that mutations in Asp63 from the loop preceding
L1 and Leu142 from L8 of FGF7 reduce FGFR2IIIb binding
and activation by about an order of magnitude, whereas mu-
tation in Arg65 from L1 has a more profound e¡ect, reducing
these activities of FGF7 by two orders of magnitude. The
theoretical model of the FGF7:FGFR2IIIb complex suggests
that these residues interact with the D3 domain of the recep-
tor. It is noteworthy that Asp63 and Arg65 are located in a
region that was previously shown by domain swapping to be
involved in FGFR2IIIb recognition [12]. The importance of
Asp63 in conferring on FGF7 subfamily members with their
speci¢c recognition of FGFR2IIIb is further underlined by the
fact that this residue is uniquely conserved in the FGF7 sub-
family and mutating the corresponding residue in FGF10
(Asp76) was found to similarly reduce the mitogenic activity
of FGF10 in Balb/MK cells [14]. Interestingly, Leu142 is
unique to FGF7 as in other FGFs there is an arginine residue
Fig. 3. The biological properties of FGF7 mutants. A: Serum-starved Balb/MK cells were stimulated with increasing concentrations of FGF7
and FGF7 mutant proteins. 16 h later, [3H]thymidine was added for 6 h and incorporation was determined as described previously [12,20].
Maximal fold increase was 25 for FGF7. B: BaF/KR cells were washed with RPMI 1640 medium and seeded at a density of 2U104 cells/well
in 96-well microtiter plates in growth medium lacking IL-3. The cells were grown in the presence of indicated concentrations of ligands and
2.5 Wg/ml heparin. The number of viable cells in the presence of FGF7 was 227 000 cells/well (about 11-fold stimulation).
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in this position. In spite of this di¡erence, mutating this argi-
nine in FGF10 (Arg155) reduced the mitogenic activity of
FGF10 in Balb/MK cells to an extent similar to that observed
by mutating Leu142 in FGF7. The crystal structure of the
FGF10:FGFR2IIIb complex suggests that Arg155 of
FGF10 forms hydrophobic contacts with the LF^LG loop
[14]. This observation, together with the present ¢ndings, sug-
gests that hydrophobic contacts are important in the interac-
tion of this residue with FGFR2IIIb in the FGF7 subfamily.
The dramatic e¡ect of the R65A mutation on FGFR2IIIb
binding a⁄nity and biological activity indicates that this res-
idue plays a key role in receptor recognition. The crystal
structure of FGF7 and our model suggest that the striking
e¡ect of the R65A mutation may result from the fact that, in
addition to interacting with D3, Arg65 is capable of forming
intramolecular hydrogen bonds that may be required for
maintaining the local conformation of the amino-terminus
of FGF7, allowing residues from this domain (including
Asp63) to interact with the receptor. Moreover, the position
of residue Arg65 in close proximity to the L4/L5 loop suggests
that it may be responsible for the correct positioning of the
L4/L5 loop in relation to D3 of the receptor. Therefore, mu-
tating this residue may have a¡ected interactions of other
residues of FGF7 with the receptor.
In addition to the above-described interactions, the theoret-
ical model of FGF7:FGFR2IIIb is in agreement with pre-
vious mutagenesis data, and together they unveil the structur-
al basis of FGF7 receptor binding speci¢city. Thus, domain
swapping and site-directed mutagenesis have identi¢ed the
important involvement of the L4/L5 loop of FGF7 in
FGFR2IIIb recognition. The model predicts that this loop
interacts with the isoform-speci¢c LCP^LE loop of D3. The
homologous domain of FGF10 was shown to similarly inter-
act with this isoform-speci¢c loop of the receptor in the
FGF10:FGFR2IIIb complex [14], emphasizing the vital role
of the L4/L5 loop in the speci¢c interaction between FGF7
subfamily members and FGFR2IIIb.
In conclusion, we have identi¢ed new domains in FGF7
that are important for the speci¢c recognition of FGFR2IIIb.
The present results complement previous mutational analyses
and together these ¢ndings reveal the structural basis for one
of the most speci¢c ligand^receptor interactions in the FGF
family, the interaction of FGF7 with FGFR2IIIb. In addition,
the fact that homologous regions in FGF7 and FGF10 are
engaged in similar speci¢c contacts with the receptor suggests
that all the members of the FGF7 subfamily utilize the same
domains to bind FGFR2IIIb.
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